Jessica A Moerland

Dr. Jessica A Moerland

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
PHPei-Yu Hung
Pei-Yu Hung
JMJessica A Moerland
Jessica A Moerland
ALAna Sofia Mendes Leal
Ana Sofia Mendes Leal
BABilal Aleiwi
Bilal Aleiwi
EEEdmund Ellsworth
Edmund Ellsworth
KLKaren T. Liby
Karen T. Liby
Background/Objectives: Neurofibromatosis type 1 (NF1) is a prevalent inherited disorder, with approximately 50% of affected individuals developing plexiform neurofibromas (PNFs), which can progress to highly aggressive malignant peripheral nerve sheath tumors (MPNSTs). While selumetinib is FDA-approved for PNFs, its efficacy in MPNSTs is limited and associated with dose-limiting toxicities. NF1 deficiency drives tumorigenesis and alters immune dynamics via RAS hyperactivation. Given the substantial macrophage infiltration in NF1 lesions and its association with disease progression, we hypothesized that targeting tumor-promoting immune cells with the retinoid X receptor (RXR) agonist MSU-42011 could be an alternative therapeutic strategy, as it has shown promise in KRAS-driven cancers by decreasing pERK levels and reducing tumor-promoting immune cells. Methods: We examined the effects of MSU-42011 and selumetinib, alone and in combination, on NF1-deficient cells and in a syngeneic MPNST model. Results: In vivo, the combination of MSU-42011 and selumetinib significantly reduced tumor growth, pERK levels, and tumor-promoting macrophages and increased activated CD8+ T cells in syngeneic MPNST models. In NF1-deficient cells, MSU-42011 or selumetinib reduced pERK levels, with combination treatment achieving greater reductions. Conditioned media (CM) from NF1-deficient cells increased the protein and mRNA levels of several cytokines and chemokines in human THP1 cells and bone marrow-derived macrophages (BMDMs). MSU-42011 and selumetinib, alone or in combination, partially reversed this induction. Conclusions: These findings suggest RXR agonists may have therapeutic potential against NF1, and their combination with MEK inhibitors could represent a promising strategy for NF1-associated tumors. Further studies are needed to validate these results and assess their translational relevance.

17 September 2026 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
SHSanya Haiaty
Sanya Haiaty
JMJessica A Moerland
Jessica A Moerland
EKEyram Kpenu
Eyram Kpenu
RWRandall S. Wireman
Randall S. Wireman
MMMahmut Mijit
Mahmut Mijit
MFMelissa L Fishel
Melissa L Fishel
Aims: Apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1) is a multifunctional protein implicated in pancreatic ductal adenocarcinoma (PDAC) through its redox regulation of oncogenic transcription factors (TFs) such as hypoxia-inducible factor 1-alpha, nuclear factor kappa-light-chain-enhancer of activated B cells, and others. While Cys65 is recognized as the primary redox-active residue, the functions of other cysteines remain only partially understood. Here, we describe the first CRISPR-engineered homozygous PDAC cell lines with single (C93A, C99A) and double (C93A + C99A) Ref-1 point mutations. This enabled detailed analysis of the individual and combined roles of Cys93 and Cys99 in Ref-1 redox signaling and their impact on various cancer phenotypes. Results: A single mutation at Cys93 decreased TF activation and reduced tumor cell survival in vitro and in vivo . These effects were similar but less pronounced in cells expressing C99A. The C93A + C99A double mutant further impaired redox signaling and decreased tumor growth and metastasis in orthotopic PDAC mouse models. All of these perturbations specifically disrupted Ref-1’s redox activity without impacting its DNA repair function. Due to reduced levels of Ref-1 protein in the C93A + C99A tumor cells, add-back experiments with wild-type Ref-1 and C93A + C99A-Ref-1 examined the impact on cell survival and activation of TFs downstream of Ref-1. Transcriptomic analysis revealed distinct changes in redox and metabolic pathways, although these were less pronounced than those observed with the previously studied C65A mutant. Innovation and Conclusion: These findings demonstrate contributory and cooperative, although secondary, roles for Cys93 and Cys99 in Ref-1 redox activity, establish new genetically engineered PDAC models, and underscore the therapeutic potential of targeting Ref-1 redox function in PDAC. Antioxid. Redox Signal. 00, 000–000.

26 November 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
COChristopher John Occhiuto
Christopher John Occhiuto
JMJessica A Moerland
Jessica A Moerland
KLKaren T. Liby
Karen T. Liby
ALAna Sofia Mendes Leal
Ana Sofia Mendes Leal
KEAP1 negatively regulates the cytoprotective factor NRF2 and is commonly inactivated in lung cancer cells. Loss-of-function KEAP1 mutations in cancer cells contribute to NRF2 activation and tumor immune evasion through immunosuppression and drug resistance. Counterintuitively, treatment with synthetic oleanane triterpenoids, potent NRF2 activators, reduces the pre-clinical tumor burden. This suggests the functional target of these drugs in cancer models is not the cancer cells but another tumor immune microenvironment (TIME) cell population. The anti-tumor potential of cells within the TIME, particularly macrophages, is potentiated by triterpenoid treatment in cancers with wild-type KEAP1 status. As KEAP1-mutant cancers show reduced tumor immune responses, triterpenoid-mediated immune stimulation may particularly benefit these cases, but this has not been investigated. To characterize the immunomodulatory effects of triterpenoids in KEAP1-mutant lung cancer, we studied tumor-educated bone marrow-derived macrophages (TE-BMDMs) and lung cancer models treated with the triterpenoids CDDO-Me or omaveloxolone. RNA-sequencing of TE-BMDMs cultured in KEAP1 KO compared to WT cancer-conditioned media had enhanced tumor-promoting phenotypes, which reversed with CDDO-Me treatment. Similarly, subcutaneous KEAP1 KO tumors were larger and more immune-suppressed compared to WT tumors. Both CDDO-Me and omaveloxolone reduced the tumor burden and improved immune cell phenotypes within the TIME independent of KEAP1 mutational status.